Abstract：
OBJECTIVE: To identify the effectiveness and safety of inactivated SARS-CoV-2 vaccines in rheumatic and musculoskeletal diseases (RMDs) patients.
METHODS: RMD patients with COVID-19 in Jiangsu Province were polled between December 8, 2022, and February 1, 2023. Information on demographics, disease characteristics, antirheumatic drug use, vaccination status and survival state were collected. COVID-19-associated pneumonia was the primary outcome. The effect of COVID-19 immunization on RMD patients was assessed using multivariate logistic regression, and the adverse events (AEs) following vaccination were evaluated.
RESULTS: Among 592 RMD patients with COVID-19, 276 (46.6%) individuals experienced COVID-19-associated pneumonia, and 290 (49.0%) patients were injected with inactivated vaccines. In multivariate logistic regression analysis, vaccines reduced the incidence of COVID-19-associated pneumonia, and receiving booster vaccine was an independent protective factor for COVID-19-associated pneumonia in RMD patients (OR 0.64, 95% CI 0.41-0.98, p = .034). In particular, inactivated vaccines have a protective impact on RMD patients with a high risk of developing pneumonia, including those aged 45 years and older (OR 0.53, 95% CI 0.34-0.83), and who have lung involvement (OR 0.43, 95% CI 0.23-0.82). The total AEs rate of vaccines was 13.9% (40/290), only 11 (3.8%) experienced the recurrence or deterioration of RMDs, and no serious AEs occurred.
CONCLUSIONS: Inactivated COVID-19 vaccines were safe and effective in reducing the risk of COVID-19-associated pneumonia of RMD patients in China.
METHODS: RMD patients with COVID-19 in Jiangsu Province were polled between December 8, 2022, and February 1, 2023. Information on demographics, disease characteristics, antirheumatic drug use, vaccination status and survival state were collected. COVID-19-associated pneumonia was the primary outcome. The effect of COVID-19 immunization on RMD patients was assessed using multivariate logistic regression, and the adverse events (AEs) following vaccination were evaluated.
RESULTS: Among 592 RMD patients with COVID-19, 276 (46.6%) individuals experienced COVID-19-associated pneumonia, and 290 (49.0%) patients were injected with inactivated vaccines. In multivariate logistic regression analysis, vaccines reduced the incidence of COVID-19-associated pneumonia, and receiving booster vaccine was an independent protective factor for COVID-19-associated pneumonia in RMD patients (OR 0.64, 95% CI 0.41-0.98, p = .034). In particular, inactivated vaccines have a protective impact on RMD patients with a high risk of developing pneumonia, including those aged 45 years and older (OR 0.53, 95% CI 0.34-0.83), and who have lung involvement (OR 0.43, 95% CI 0.23-0.82). The total AEs rate of vaccines was 13.9% (40/290), only 11 (3.8%) experienced the recurrence or deterioration of RMDs, and no serious AEs occurred.
CONCLUSIONS: Inactivated COVID-19 vaccines were safe and effective in reducing the risk of COVID-19-associated pneumonia of RMD patients in China.
摘要：
目的：确定灭活的SARS-CoV-2疫苗在风湿性和肌肉骨骼疾病（RMDs）患者中的有效性和安全性。
方法：在2022年12月8日至2023年2月1日期间，对江苏省患有COVID-19的RMD患者进行了调查。人口统计信息，疾病特征，抗风湿药的使用，收集疫苗接种状态和生存状态。COVID-19相关性肺炎是主要结果。COVID-19免疫对RMD患者的影响使用多变量logistic回归评估，并评估疫苗接种后的不良事件（AE）。
结果：在592例患有COVID-19的RMD患者中，276例（46.6％）个体经历了COVID-19相关性肺炎，290例(49.0%)患者注射了灭活疫苗。在多变量逻辑回归分析中，疫苗降低了COVID-19相关性肺炎的发病率，接受加强疫苗接种是RMD患者COVID-19相关性肺炎的独立保护因素(OR0.64,95%CI0.41-0.98,p=.034)。特别是,灭活疫苗对患有肺炎高风险的RMD患者具有保护性影响，包括45岁及以上的人群(OR0.53，95%CI0.34-0.83)，并且有肺部受累（OR0.43，95％CI0.23-0.82）。疫苗的总不良事件发生率为13.9%(40/290)，只有11人(3.8%)经历了RMD的复发或恶化，无严重不良事件发生。
结论：灭活COVID-19疫苗可安全有效地降低中国RMD患者的COVID-19相关性肺炎风险。
方法：在2022年12月8日至2023年2月1日期间，对江苏省患有COVID-19的RMD患者进行了调查。人口统计信息，疾病特征，抗风湿药的使用，收集疫苗接种状态和生存状态。COVID-19相关性肺炎是主要结果。COVID-19免疫对RMD患者的影响使用多变量logistic回归评估，并评估疫苗接种后的不良事件（AE）。
结果：在592例患有COVID-19的RMD患者中，276例（46.6％）个体经历了COVID-19相关性肺炎，290例(49.0%)患者注射了灭活疫苗。在多变量逻辑回归分析中，疫苗降低了COVID-19相关性肺炎的发病率，接受加强疫苗接种是RMD患者COVID-19相关性肺炎的独立保护因素(OR0.64,95%CI0.41-0.98,p=.034)。特别是,灭活疫苗对患有肺炎高风险的RMD患者具有保护性影响，包括45岁及以上的人群(OR0.53，95%CI0.34-0.83)，并且有肺部受累（OR0.43，95％CI0.23-0.82）。疫苗的总不良事件发生率为13.9%(40/290)，只有11人(3.8%)经历了RMD的复发或恶化，无严重不良事件发生。
结论：灭活COVID-19疫苗可安全有效地降低中国RMD患者的COVID-19相关性肺炎风险。
